Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial
about
Human IL-6RhiTIGIT- CD4+CD127lowCD25+ T cells display potent in vitro suppressive capacity and a distinct Th17 profile.In-depth immunophenotyping data of IL-6R on the human peripheral regulatory T cell (Treg) compartment.Gene therapy with an AAV vector expressing human IL-2 alters immune system homeostasis in humanized mice.FOCIS goes south: advances in translational and clinical immunology.Capturing the systemic immune signature of a norovirus infection: an n-of-1 case study within a clinical trial.Unique Features of Pancreatic-Resident Regulatory T Cells in Autoimmune Type 1 Diabetes.Attenuated IL-2R signaling in CD4 memory T cells of T1D subjects is intrinsic and dependent on activation state.Engineered Tolerance: Tailoring Development, Function, and Antigen-Specificity of Regulatory T Cells.Harnessing the power of regulatory T-cells to control autoimmune diabetes: overview and perspective.CD11a/ICAM-1 blockade combined with IL-2 targeting therapy causes a paradoxical acceleration of type 1 diabetes.Formalising recall by genotype as an efficient approach to detailed phenotyping and causal inference.New Horizons in the Treatment of Type 1 Diabetes: More Intense Immunosuppression and Beta Cell Replacement.Interactions Between the Neuroendocrine System and T Lymphocytes in Diabetes.Evidence that UBASH3 is a causal gene for type 1 diabetes.Low-dose interleukin-2 in patients with stable ischaemic heart disease and acute coronary syndromes (LILACS): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase I/II clinical trial
P2860
Q33800947-40FB2213-6F97-43F3-A172-1C66615231F4Q36388184-D35AB054-80A5-4DE6-B837-93079998326CQ38616032-2C35A81D-69CC-485C-96D7-4AF70636766DQ40064195-620912E9-B61B-42A4-BF0E-F7D43F4770A9Q40080595-A1C549EF-21E7-4D40-9D82-6944A41292BCQ42369832-60009B68-F8EF-4CD0-81EC-944CE60567CBQ42511453-4F572DEE-E8C3-47FE-953A-BBF949FF45CFQ47150746-E44ACDC2-C1EA-42AF-AC62-E5193FC4C1DEQ47385058-E05266E3-AF08-430D-B5A2-4D9D5593F969Q48282629-9D6887D1-4FD5-40F0-AE24-50405715C098Q49830020-7FF942E9-88A7-4008-83BA-29328B78CCFAQ55195712-4CFCDD1C-0074-4E2D-88F4-3FF0BDE9FD27Q55337327-A39E9473-F5FF-42C3-908B-2FE42BB3317FQ55380026-68330233-A61F-4FA6-B3CD-C7A2110F913EQ58732372-B1679AB7-9E0F-4FC5-B8B7-9BB566721B1E
P2860
Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial
description
2016 nî lūn-bûn
@nan
2016 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Regulatory T Cell Responses in ...... l, Adaptive Dose-Finding Trial
@ast
Regulatory T Cell Responses in ...... l, Adaptive Dose-Finding Trial
@en
Regulatory T Cell Responses in ...... l, Adaptive Dose-Finding Trial
@nl
type
label
Regulatory T Cell Responses in ...... l, Adaptive Dose-Finding Trial
@ast
Regulatory T Cell Responses in ...... l, Adaptive Dose-Finding Trial
@en
Regulatory T Cell Responses in ...... l, Adaptive Dose-Finding Trial
@nl
prefLabel
Regulatory T Cell Responses in ...... l, Adaptive Dose-Finding Trial
@ast
Regulatory T Cell Responses in ...... l, Adaptive Dose-Finding Trial
@en
Regulatory T Cell Responses in ...... l, Adaptive Dose-Finding Trial
@nl
P2093
P2860
P50
P3181
P1433
P1476
Regulatory T Cell Responses in ...... l, Adaptive Dose-Finding Trial
@en
P2093
Adrian P Mander
Ben Challis
Charles J M Bell
Daniel B Rainbow
Donna Goymer
Gillian Coleman
Helen E Stevens
Jane Greatorex
Jane Kennet
Jennie H Yang
P2860
P304
P3181
P356
10.1371/JOURNAL.PMED.1002139
P407
P50
P577
2016-10-11T00:00:00Z